Skip to search formSkip to main contentSkip to account menu

zolmitriptan

Known as: zolmitriptan [Chemical/Ingredient], (S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one, 4-[[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one 
A member of the triptan class of agents with anti-migraine properties. Zolmitriptan selectively binds to and activates serotonin (5-HT) 1B receptors… 
National Institutes of Health

Related topics

Related topics

19 relations

Narrower (3)

311C90FlezolZomig
Angina Pectoris, VariantCerebral Arterial Vasoconstriction [PE]Drug AllergyHypertensive disease

Broader (3)

OxazolidinonesSerotonin 5-HT1 Receptor AgonistsTryptamines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Excellent Tolerability But Relatively Low Initial Clinical Efficacy of Telcagepant in Migraine
(Headache 2011;51:118‐123) 
Review
2007
Review
2007
Acute treatment of paediatric migraine: A meta‐analysis of efficacy
Aim:  To undertake a meta‐analysis of all randomised controlled trials (RCTs) on the acute pharmacologic treatment of children… 
2006
2006
Blood–Brain Barrier Penetration of Zolmitriptan—Modelling of Positron Emission Tomography Data
Positron emissiontomography (PET) with the drug radiolabelled allows a direct measurement of brain or other organ kinetics… 
2005
2005
Zolmitriptan Nasal Spray Exhibits Good Long‐Term Safety and Tolerability in Migraine: Results of the INDEX Trial
Background.—Previous studies have shown that zolmitriptan 5 mg nasal spray has a fast onset of action, high efficacy, and good… 
2003
2003
Tolerability and Consistency of Effect of Zolmitriptan Nasal Spray in a Long-Term Migraine Treatment Trial
AbstractObjectives: To primarily assess the tolerability of zolmitriptan (Zomig®) nasal spray 5mg in the long-term treatment of… 
Review
2001
Review
2001
Current options for the prevention and treatment of migraine.
2001
2001
4991W93, a potent blocker of neurogenic plasma protein extravasation, inhibits trigeminal neurons at 5-hydroxytryptamine (5-HT1B/1D) agonist doses
2001
2001
An Open Preference Study with Sumatriptan 50 mg and Zolmitriptan 2.5 mg in 100 Migraine Patients
Understanding factors influencing patients' preference will improve guidance to make rational choices in expanded symptomatic… 
1998
1998
Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist.
1997
1997
Peripheral Vascular Effects and Pharmacokinetics of the Antimigraine Compound, Zolmitriptan, in Combination with Oral Ergotamine in Healthy Volunteers
Members of the new class of antimigraine compounds, 5HT1B/1D agonists, as well as ergotamine, may cause vasoconstriction through… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)